Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020
Summary
Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.
Scope
Reasons to Buy
Summary
Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.
Scope
- Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, 5EU, Japan, Canada)
- Summary of primary research with Immunology Key Opinion Leaders
- Forward-looking perspective of potential long-term ramifications of COVID pandemic
Reasons to Buy
- Understand the impact of COVID-19 on immunology clinical trials
- Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
- Understand the impact of COVID on continuity of care for immunology patients
- Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
- Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice
Table of Contents
1 Immunology Trials Disrupted
3 KOL Insights: Trial Logistics
4 KOL Insights: Trials Looking Forward
5 Appendix
